CVS Health Corporation (CVS) fair value analysis

S&P 500 · Updated 2026-09-07

CVS Health Corporation operates as an integrated pharmacy and healthcare company providing prescription medications, over-the-counter products, and health services through its retail pharmacy network. The company operates pharmacy locations and clinics throughout the United States under the CVS brand name.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, CVS is trading at a 10–25% premium to estimated fair value.

CVS currently ranks #92 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $96.74
Sector: Healthcare
12-month range: $72.49–$105.37

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: F
Leverage: Moderate
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The upper-middle quarter of its range
DCF cross-check: Overvalued

What our data shows for CVS

Our model validated 17 trailing price-to-earnings windows for CVS, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $72.49–$105.37.
The 14-day relative strength index sits at a neutral 48.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for CVS
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent CVS news

TickrTrends' derived news-sentiment signal for CVS is currently leaning positive, computed from recent coverage.

Jim Cramer Says “Own It, Don’t Trade It” as CVS Health Gains Momentum (insidermonkey.com, 2026-09-05)
TickrTrends take: CVS Health currently trades at a valuation that TickrTrends classifies as overvalued within the Healthcare sector, which creates a tension with commentary suggesting the stock warrants a longer-term holding approach. Investors focused on valuation metrics should monitor whether CVS's operational momentum can narrow the gap between its current trading price and fundamental value, or whether the overvaluation assessment reflects a disconnect between near-term business performance and longer-term value creation. The Healthcare sector's dynamics and CVS's competitive position will be important factors in determining whether current price levels become justified over time.
Is CVS Health Outperforming the Nasdaq? (finance.yahoo.com, 2026-09-04)
TickrTrends take: CVS Health's performance relative to the broader market provides important context for assessing whether its current market price reflects its underlying fundamentals. Given TickrTrends' overvalued designation, investors focused on valuation metrics should monitor whether any outperformance against the Nasdaq is being driven by improving operational efficiency and earnings growth, or if it primarily reflects market momentum that may not be justified by the company's healthcare sector fundamentals. The gap between CVS's stock performance and its valuation assessment suggests tracking the company's ability to generate returns that would eventually justify its current trading levels.
CVS Looks 23.3% Overvalued on GF Value™ as Dividend Sustainability Remains a Key Focus (gurufocus.com, 2026-09-01)
TickrTrends take: CVS is trading at a significant premium to its estimated intrinsic value according to GF Value analysis, which aligns with TickrTrends' overvalued assessment. For investors focused on valuation metrics, the company's dividend sustainability warrants close monitoring given the current premium pricing, as the Healthcare sector often attracts income-focused investors who require confidence in long-term payout security. The gap between market price and estimated fair value suggests potential downside risk should the company face earnings pressures or if market sentiment toward dividend-paying healthcare stocks shifts.

What people are saying

Follow the CVS conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — CVS's Relative Strength Index moved from oversold territory into neutral range this week, suggesting a shift in momentum dynamics for the healthcare stock. The company remains classified as overvalued according to TickrTrends' derived valuation metrics.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is CVS stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), CVS is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is CVS's TickrTrends verdict?

CVS's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does CVS compare to other Healthcare stocks?

CVS ranks #92 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is CVS overbought or oversold?

CVS's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

CVS vs BIO · CVS vs CAH · CVS vs CNC · CVS vs INMD · CVS vs LH